汇宇制药：HYP - 6589片联合用药获药物临床试验批准

Core Viewpoint - Huiyu Pharmaceutical's subsidiary, Huiyu Haiyue, has received approval from the National Medical Products Administration for clinical trials of the innovative chemical drug HYP-6589 (development code "HY-0006") in combination with Osimertinib for the treatment of advanced non-small cell lung cancer with target-driven gene positivity [1] Group 1 - The drug HYP-6589 is classified as a first-class innovative chemical drug and was accepted for registration on November 21, 2025 [1] - As of the announcement date, there are no similar products approved for market release domestically or internationally [1] - The company acknowledges the long development cycle and high investment risks associated with new drug research and will advance the project while providing timely updates on progress [1]